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Introduction: Patients with Type 2 diabetes (T2D) are commonly initiated onto premixed 
insulin (premix) when oral antidiabetic agents (OADs) no longer provide adequate glycaemic 
control. This subanalysis examined how patients in European countries rated their treatment 
satisfaction as part of a clinical trial. 
Methods: Men and women (n=364), aged 45–75 years with T2D and HbA1c=7.5–10.5% on 
OADs, received either glargine+OADs (glimepiride and metformin) or twice-daily premix 
(30% regular/70% NPH insulin) without OADs in this multinational (n=10), multicentre 
(n=66), parallel-group, open-label, randomized clinical trial. Patients completed the 8-item 
Diabetes Treatment Satisfaction Questionnaire (DTSQs; status version) at baseline and 
endpoint, and the DTSQc (change version) at endpoint. Treatment satisfaction scores 
ranged from 36.0 to 0 (DTSQs) and 18 to –18 (DTSQc): higher scores indicate 
greater/improved satisfaction. Treatment group differences were evaluated using ANCOVA, 
(treatment and language entered as fixed factors; baseline values as covariates).  
Results: At baseline, there was no difference in treatment satisfaction between treatment 
groups (p[treatment]=0.36) though there was a significant effect of language (p[language]=0.0027). 
Improvements in DTSQs score were, in the total sample, greater for patients in the 
glargine+OAD group (baseline=26.9±7.3; baseline–endpoint difference=4.0±8.2) compared 
with premix (baseline=26.3±7.1; difference=2.3±9.5; p[treatment]=0.0022; p[language]=0.35). Dutch 
and English subsamples were exceptions where ceiling effects on the DTSQs at baseline 
were greater than other language groups and limited the improvements in DTSQs scores 
from baseline to endpoint in these Dutch (baseline: glargine+OAD=30.3±5.7, 
premix=29.3±5.0; difference glargine+OAD=3.0±5.3, premix=4.3±6.4) and English (baseline: 
glargine+OAD=31.1±1.9, premix=31.7±6.7; difference: glargine+OAD=1.5±3.1, 
premix=3.0±7.9) patients. Significantly higher scores for DTSQc were reported by the 
glargine+OAD group (glargine+OAD=14.0±5.3; premix=11.5±6.7; p=0.0028); a pattern seen 
in all countries. 
Discussion: Ceiling effects at baseline distorted DTSQs results in two countries. The 
DTSQc overcame the ceiling effects and showed that initiating insulin therapy with 
glargine+OADs is associated with significant improvements in treatment satisfaction in all 
countries involved.  
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